Townsquare Capital LLC Invests $546,000 in ADMA Biologics Inc $ADMA

Key Points

• Townsquare Capital LLC made a new investment of approximately $546,000 in ADMA Biologics, acquiring 27,521 shares of the stock in the first quarter.
• Several institutional investors, including Citigroup Inc. and Charles Schwab Investment Management Inc., have increased their holdings in ADMA Biologics, with institutional ownership now at 75.68%.
• ADMA Biologics reported a net margin of 44.06% and a revenue of $121.98 million during its recent quarterly earnings, reflecting a 13.8% increase compared to the previous year.

Townsquare Capital LLC acquired a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 27,521 shares of the biotechnology company's stock, valued at approximately $546,000.

Several other large investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after purchasing an additional 643,661 shares in the last quarter. Oberweis Asset Management Inc. boosted its position in shares of ADMA Biologics by 15.0% during the 4th quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock valued at $57,325,000 after purchasing an additional 435,480 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of ADMA Biologics by 7.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after purchasing an additional 207,097 shares in the last quarter. Northern Trust Corp boosted its position in shares of ADMA Biologics by 6.0% during the 4th quarter. Northern Trust Corp now owns 2,575,075 shares of the biotechnology company's stock valued at $44,163,000 after purchasing an additional 145,387 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of ADMA Biologics by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,462,005 shares of the biotechnology company's stock valued at $48,846,000 after purchasing an additional 21,711 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 1.2%

ADMA stock traded down $0.2150 during mid-day trading on Thursday, reaching $17.0850. 137,560 shares of the stock traded hands, compared to its average volume of 3,121,601. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The company has a market cap of $4.08 billion, a P/E ratio of 19.87 and a beta of 0.38. The stock's fifty day moving average is $18.06 and its 200-day moving average is $18.86.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the firm earned $0.13 earnings per share. The business's quarterly revenue was up 13.8% on a year-over-year basis. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial raised their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $27.67.

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 455,621 shares of company stock valued at $9,461,633. 3.50% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.